Wageningen, The Netherlands
January 12, 2006
The new proprietary Complexity
Reduction of Polymorphic Sequences, CRoPSTM, technology
developed by Keygene
enables large scale polymorphism discovery and detection in
higher eukaryotic organisms including plants with very large
genomes by a combination of AFLP®-mediated DNA complexity
reduction methods and the power of high throughput sequencing.
Keygene selected and purchased the
Genome Sequencer 20 system developed by 454 Life Sciences and
distributed by Roche Applied Science as the only platform
available today with sufficient throughput for the practice of
the CRoPSTM method. Keygene will work in close collaboration
with 454 Life Sciences to develop other proprietary applications
in the field of plant genetics that are unlocked by the use of
454 Life Sciences' technology in combination with Keygene's
existing DNA expertise and SNPWaveTM technology. For this, a
research collaboration agreement between 454 Life Sciences and
Keygene has been executed.
The CRoPSTM technology platform
will be presented to the scientific community by Keygene during
the Plant & Animal Genome conference in San Diego (January
14-18, 2006).
"The 454 technology, in
combination with Keygene's current technology platform, creates
many new opportunities that further increase the efficiency of
genotyping in plant species, of which the CRoPSTM technology is
the first example", says Michiel van Eijk, manager Upstream
Research of Keygene.
Arjen van Tunen, CEO of Keygene,
adds that "strategically the collaboration with 454 Life
Sciences will enable Keygene to maintain its position as a
leading DNA company, enabling better solutions for our strategic
research partners and customers".
Keygene N.V. is a R&D company
with the mission to be the leading company in developing and
applying DNA expertise in the field of molecular genetics for
its shareholder breeding companies. Keygene has developed a
strong proprietary technology platform based on AFLP®, a DNA
marker technology for genome analysis, transcript profiling and
genetic analysis. For diagnostic purposes, SNPWave™, a
multiplexed SNP detection technology was developed. Keygene
exploits its proprietary technologies, databases and know-how
through contract research and products for applications in the
Life Sciences industry and more specifically in innovative
breeding applications such as Breeding by Design™. Keygene has
five shareholders consisting of major vegetable seed companies
that collaborate in the BioSeeds strategic alliance: De Ruiter
Seeds, ENZA Zaden, Rijk Zwaan, Vilmorin Clause & Cie and Takii &
Co. Keygene has around 100 researchers and staff.
The AFLP® technology, SNPWave™
technology and CRoPS™ technology are covered by patents and/or
patent applications of Keygene N.V. AFLP is a registered
trademark of Keygene N.V. Applications for trademark
registration for Breeding by Design, SNPWave and CRoPS have been
filed by Keygene N.V. |